FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Secondary prevention of hidradenitis suppurativa
3122PDF: 1254HTML: 45 -
Cutaneous manifestation of polycystic ovary syndrome
3002PDF: 1195HTML: 71 -
24 | IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL E. Filippi1, M. Lebwohl2, A. Blauvelt3, C. Kartman4, C. Leatherwood4, K. Gordon5, N. Sattar6, L. Puig7, J. Merola8, K. Siu4, R. Wang4, L. Sun4, A. Leung9, N. Somani4, M. Rueda4, A. Cardoso4, M. Genovese4, A. Armstrong10, B. Strober11 | 1Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy; 2Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3Blauvelt Consulting, LLC, Annapolis, MD, USA; 4Eli Lilly and Company, Indianapolis, IN, USA; 5Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; 6School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; 7Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain; 8Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; 9Syneos Health, Morrisville, NC, USA; 10Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA; 11Department of Dermatology, Yale University School of Medicine, New Haven, CT, Central Connecticut Dermatology Research, Cromwell, CT, USA
99PDF: 31 -
26 | CONCOMITANT THERAPY WITH IXEKIZUMAB PLUS TIRZEPATIDE IN ADULTS WITH PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY DEMONSTRATED SUPERIOR DISEASE CONTROL COMPARED TO IXEKIZUMAB ALONE: RESULTS FROM THE PH3B TOGETHER-PSA TRIAL E. Filippi1, J. F. Merola2, P. Mease3, A. Kivitz4, N. Sattar5, L. C. Coates6, C. E. Kartman7, P. Fischer7, L. Sun7, A. Cardoso7, M. C. Genovese7, A. Ogdie8 | 1Eli Lilly Italia S.p.A, Florence, Italy; 2Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; 3Providence Swedish Medical Center, Seattle, WA, USA; 4Altoona Center for Clinical Research, Duncansville, PA, USA; 5School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 7Eli Lilly and Company, Indianapolis, IN, USA; 8Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
101PDF: 26 -
The top 100 most cited articles in acne vulgaris: a bibliometric analysis
3361PDF: 615SUPPLEMENTARY MATERIAL: 201HTML: 26 -
Erythrodermic psoriasis improved by tildrakizumab
1369PDF: 642HTML: 28 -
A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain
896PDF: 322SUPPLEMENTARY MATERIAL: 121

